---
course_id: 7-341-the-dna-damage-response-as-a-target-for-anti-cancer-therapy-fall-2008
layout: course_section
menu:
  leftnav:
    identifier: 9a674d234170a59c343b5ccf693bc793
    name: Readings
    weight: 20
title: Readings
type: course
uid: 9a674d234170a59c343b5ccf693bc793

---

This section also contains [suggested readings](#suggested_readings) for the course.

Required Readings
-----------------

| SES # | TOPICS | READINGS |
| --- | --- | --- |
| 1 | Introduction | &nbsp; |
| 2 | The cell cycle |  {{< br >}}{{< br >}} Pines, J., and T. Hunter. "[Isolation of a Human Cyclin cDNA: Evidence for Cyclin mRNA and Protein Regulation in the Cell Cycle and for Interaction with p34cdc2](http://www.ncbi.nlm.nih.gov/pubmed/2570636)." _Cell_ 58 (1989): 833-46. {{< br >}}{{< br >}} Simanis, V., and P. Nurse. "[The Cell Cycle Control Gene cdc2+ of Fission Yeast Encodes a Protein Kinase Potentially Regulated by Phosphorylation](http://www.ncbi.nlm.nih.gov/pubmed/3516412)." _Cell_ 45 (1986): 261-8. {{< br >}}{{< br >}}  |
| 3 | Cell cycle control – the role of the tumor suppressor pRb in the G1/S transition |  {{< br >}}{{< br >}} Hartwell, L. H., J. Culotti, and B. Reid. "[Genetic Control of the Cell-division Cycle in Yeast, I. Detection of Mutants](http://www.pnas.org/content/66/2/352.abstract)." _PNAS_ 66 (1970): 352-9. {{< br >}}{{< br >}} Goodrich, D. W., N. P. Wang, Y. W. Quan, E. Lee, and W. H. Lee. "[The Retinoblastoma Gene Product Regulates Progression Through the G1 Phase of the Cell Cycle](http://www.ncbi.nlm.nih.gov/pubmed/1655277)." _Cell_ 67 (1991): 293-302. {{< br >}}{{< br >}}  |
| 4 | Cdk-regulation |  {{< br >}}{{< br >}} Parker, L. L., and H. Piwnica-Worms. "[Inactivation of the p34cdc2-Cyclin B Complex by the Human WEE1 Tyrosine Kinase](http://www.ncbi.nlm.nih.gov/pubmed/1384126)." _Science_ 257 (1992): 1955-1957. {{< br >}}{{< br >}} Gautier, J., M. J. Solomon, R. N. Booher, J. F. Bazan, and M. W. Kirschner. "[cdc25 is a Specific Tyrosine Phosphatase that Directly Activates p34cdc2](http://www.ncbi.nlm.nih.gov/pubmed/1913817)." _Cell_ 67 (1991): 197-211. {{< br >}}{{< br >}}  |
| 5 | Checkpoint control of the cell cycle |  {{< br >}}{{< br >}} Matsuoka, S., M. Huang, and S. J. Elledge. "[Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase](http://www.sciencemag.org/cgi/content/abstract/282/5395/1893)." _Science_ 282 (1998): 1893-7. {{< br >}}{{< br >}} Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. "[Radiation-induced Cell Cycle Arrest Compromised by p21 Deficiency](http://www.nature.com/nature/journal/v377/n6549/abs/377552a0.html)." _Nature_ 377 (1995): 552-7. {{< br >}}{{< br >}}  |
| 6 | p53 regulation |  {{< br >}}{{< br >}} Hirao, A., Y. Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D. Liu, S. J. Elledge, and T. W. Mak. "[DNA Damage-induced Activation of p53 by the Checkpoint Kinase Chk2](http://stke.sciencemag.org/cgi/content/abstract/sci;287/5459/1824)." _Science_ 287 (2000): 1824-7. {{< br >}}{{< br >}} Honda R., and H. Yasuda. "[Association of p19ARF with Mdm2 Inhibits Ubiquitin Ligase Activity of Mdm2 for Tumor Suppressor p53](http://dx.doi.org/10.1093/emboj/18.1.22)." _The EMBO Journal_ (1999) 18, 22-27. {{< br >}}{{< br >}}  |
| 7 | The DNA damage checkpoint differs depending on cell cycle stage |  {{< br >}}{{< br >}} Jazayeri, A., J. Falck, C. Lukas, J. Bartek, G. C. Smith, J. Lukas, and S. P. Jackson. "[ATM- and Cell Cycle-dependent Regulation of ATR in Response to DNA Double-strand Breaks](http://www.nature.com/ncb/journal/v8/n1/abs/ncb1337.html)." _Nature Cell Biology_ 8 (2006): 37-45. {{< br >}}{{< br >}} Jin, J., J. Shirogane, L. Xu, G. Nalepa, J. Qin, S. J. Elledge, and J. W. Harper. "[SCFβ-TRCP Links Chk1 Signaling to Degradation of the Cdc25A Protein Phosphatase](http://genesdev.cshlp.org/content/17/24/3062.abstract)." _Genes & Development_ 17 (2003): 3062-3074. {{< br >}}{{< br >}}  |
| 8 | 'To die or not to die' – the decision between repair and apoptosis |  {{< br >}}{{< br >}} Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein. "[PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells](http://www.ncbi.nlm.nih.gov/pubmed/11463391)." _Molecular Cell_ 7 (2001): 673-82. {{< br >}}{{< br >}} Adimoolam, S., and J. M. Ford. "[p53 and DNA Damage-inducible Expression of the Xeroderma Pigmentosum Group C Gene](http://www.pnas.org/content/99/20/12985.full)." _Proc Natl Acad Sci U S A_ 99 (2002): 12985-90. {{< br >}}{{< br >}}  |
| 9 | Structural insights into the DNA damage response |  {{< br >}}{{< br >}} Moreno-Herrero, F., M. de Jager, N. H. Dekker, R. Kanaar, C. Wyman, and C. Dekker. " [Mesoscale Conformational Changes in the DNA-repair Complex Rad50/Mre11/Nbs1 Upon Binding DNA](http://dx.doi.org/10.1038/nature03927)." _Nature_ 437 (2005):440-3. {{< br >}}{{< br >}} Stucki, M., J. A. Clapperton, D. Mohammad, M. B. Yaffe, S. J. Smerdon, and S. P. Jackson. "[MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-strand Breaks](http://www.ncbi.nlm.nih.gov/pubmed/16377563)." _Cell_ 123 (2005):1213-26. {{< br >}}{{< br >}}  |
| 10 | Field trip: visit to an MIT Biology laboratory | &nbsp; |
| 11 | Defective DNA damage responses and cancer |  {{< br >}}{{< br >}} Lam, M. H., Q. Liu, S. J. Elledge, and J. M. Rosen. "[Chk1 is Haploinsufficient for Multiple Functions Critical to Tumor Suppression](http://www.cell.com/cancer-cell/retrieve/pii/S1535610804001758)." _Cancer Cell_ 6 (2004): 45-59. {{< br >}}{{< br >}} Ventura, A., D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks. "[Restoration of p53 Function Leads to Tumour Regression _In vivo_](http://dx.doi.org/10.1038/nature05541)." _Nature_ 445 (2007): 661-5. {{< br >}}{{< br >}}  |
| 12 | Checkpoint-related syndromes |  {{< br >}}{{< br >}} Gilad, S., L. Chessa, R. Khosravi, P. Russell, Y. Galanty, M. Piane, R. A. Gatti, T. J. Jorgensen, Y. Shiloh, and A. Bar-Shira. "[Genotype-Phenotype Relationships in Ataxia-Telangiectasia and Variants](http://www.ncbi.nlm.nih.gov/pubmed/9497252)." _American Journal of Human Genetics_ 62 (1998): 551-61. {{< br >}}{{< br >}} Bell, D. W., J. M. Varley, T. E. Szydlo, D. H. Kang, D. C. Wahrer, K. E. Shannon, M. Lubratovich, S. J. Verselis, K. J. Isselbacher, J. F. Fraumeni, J. M. Birch, F. P. Li, J. E. Garber, and D. A. Haber. "[Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome](http://www.ncbi.nlm.nih.gov/pubmed/10617473)." _Science_ 286 (1999): 2528-31. {{< br >}}{{< br >}}  |
| 13 | Cancer treatment based on knowledge about the DNA damage response – targeted therapeutics |  {{< br >}}{{< br >}} Farmer, H., N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith, and A. Ashworth. "[Targeting the DNA Repair Defect in BRCA Mutant cells as a Therapeutic Strategy](http://www.ncbi.nlm.nih.gov/pubmed/15829967)." _Nature_ 434 (2005): 917-21. {{< br >}}{{< br >}} Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U.Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu EA. "[_In vivo_ Activation of the p53 Pathway by Small-molecule Antagonists of MDM2](http://www.ncbi.nlm.nih.gov/pubmed/14704432)." _Science_ 303 (2004): 844-8. {{< br >}}{{< br >}}  |
| 14 | Cancer treatment based on specific mutations that "drive" malignant growth – exploiting oncogene addiction |  {{< br >}}{{< br >}} Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmerman, and N. B. Lydon. "[Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells](http://www.ncbi.nlm.nih.gov/pubmed/8616716)." _Nature Med_ 2 (1996): 561-6. {{< br >}}{{< br >}} Paez, J. G., et al. "[EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy](http://www.ncbi.nlm.nih.gov/pubmed/15118125)." _Science_ 304 (2004): 1497-1500. {{< br >}}{{< br >}}  |
| 15 | In-class presentations |   

{{< anchor "suggested_readings" >}}{{< /anchor >}}Suggested Readings
--------------------------------------------------------------------

Bartek, J., J. Bartkova, and J. Lukas. "DNA Damage Signalling Guards Against Activated Oncogenes and Tumour Progression." _Oncogene_ 26 (2007): 7773-9.

Bartek, J., F. Falck, and J. Lukas. "CHK2 Kinase - A Busy Messenger." _Nature Reviews_ 2 (2001): 877-86.

Bartek, J., and J. Lukas. "DNA Damage Checkpoints: From Initiation to Recovery or Adaptation. " _Curr Op Cell Biol_ 19 (2007) 238-45.

Hanks, S. K., and T. Hunter. "The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification." _FASEB Journal_ 9 (1995): 576-586.

Harper, J. W., and S. J. Elledge. "The DNA Damage Response: Ten Years After." _Mol Cell_ 28 (2007): 739-45.

Kastan, M. B., and J. Bartek. "Cell-cycle Checkpoints and Cancer." _Nature_ 432 (2004): 316-323.

Kastan, M. B., and D. Lim. "The Many Substrates and Functions of ATM." _Nature Reviews: Molecular Cell Biology_ 1 (2000): 179-186.

Kawabe, T. "G2 Checkpoint Abrogators as Anticancer Drugs." _Molecular Cancer Therapeutics_ 3 (2004): 513-519.

Sancar, A., L. A. Lindsey-Boltz, K. Unsal-Kacmaz, and S. Linn. "Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints." _Ann Rev Biochem_ 73 (2004): 39-85.

Shiloh, Y. "ATM and Related Protein Kinases: Safeguarding Genome Integrity." _Nature Reviews: Cancer_ 3 (2003): 155-168.

Zhou, B. S., and J. Bartek. "Targeting the Checkpoint Kinases: Chemosensitization versus Chemoprotection." _Nature Reviews: Cancer_ 4 (2004): 1-10.

Zhou, B. S., and S. J. Elledge. "The DNA Damage Response: Putting Checkpoints in Perspective." _Nature_ 408 (2000): 433-439.